Understanding general practitioner and pharmacist preferences for pharmacogenetic testing in primary care: a discrete choice experiment.
Pharmacogenomics J
; 24(5): 25, 2024 Aug 09.
Article
in En
| MEDLINE
| ID: mdl-39122683
ABSTRACT
Pharmacogenetic testing in the United Kingdom's National Health Service (NHS) has historically been reactive in nature, undertaken in the context of single gene-drug relationships in specialist settings. Using a discrete choice experiment we aimed to identify healthcare professional preferences for development of a pharmacogenetic testing service in primary care in the NHS. Respondents, representing two professions groups (general practitioners or pharmacists), completed one of two survey versions, asking them to select their preferred pharmacogenetic testing service in the context of a presentation of low mood or joint pain. Responses from 235 individuals were included. All respondents preferred pharmacogenetic testing over no testing, though preference heterogeneity was identified. Both professional groups, but especially GPs, were highly sensitive to service design, with uptake varying depending on the service offered. This study demonstrates uptake of a pharmacogenetic testing service is impacted by service design and highlights key areas which should be prioritised within future initiatives.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pharmacists
/
Primary Health Care
/
General Practitioners
/
Pharmacogenomic Testing
Limits:
Adult
/
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Europa
Language:
En
Journal:
Pharmacogenomics J
Journal subject:
BIOLOGIA MOLECULAR
/
FARMACOLOGIA
Year:
2024
Document type:
Article
Country of publication:
United States